Frans Erdkamp

Publications by Year

Research Areas

Cancer Treatment and Pharmacology, Advanced Breast Cancer Therapies, Breast Cancer Treatment Studies, HER2/EGFR in Cancer Research, Cancer Genomics and Diagnostics

Most-Cited Works

• → Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer(2009)1,350 cited
• → Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial(2007)629 cited
• → Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial(2018)565 cited
• → Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group(2015)519 cited
• → Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis(2013)514 cited
• → Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial(2019)278 cited
• → Effects of an 18-week exercise programme started early during breast cancer treatment: a randomised controlled trial(2015)233 cited
• → A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity(2008)213 cited
• → Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper(2010)166 cited
• → First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group(2023)159 cited